Synairgen announces its inhaled interferon beta (SNG001) is advancing to Phase 3 of the NIH-sponsored ACTIV-2 COVID-19 Trial
20. Oktober 2021 07:00 ET
|
Synairgen plc
Synairgen plc(‘Synairgen’ or the ‘Company’) Synairgen announces its inhaled interferon beta (SNG001) is advancing to Phase 3 of the NIH-sponsored ACTIV-2 COVID-19 Trial Southampton, UK – 20 October...
Interim results for the six months ended 30 June 2021
30. September 2021 07:00 ET
|
Synairgen plc
Synairgen plc(‘Synairgen’ or the ‘Company’) Interim results for the six months ended 30 June 2021 Scaling up and preparing for Phase III COVID-19 trial data read-out Webcast today at 13:00 BST ...
Non-Executive Director Appointment
30. September 2021 07:00 ET
|
Synairgen plc
Synairgen plc(‘Synairgen’ or the ‘Company’) Non-Executive Director Appointment Southampton, UK – 30 September 2021: Synairgen plc (LSE: SNG), the drug discovery, development and commercialisation...
Non-Executive Director Appointment
30. September 2021 02:02 ET
|
Synairgen plc
Synairgen plc(‘Synairgen’ or the ‘Company’) Non-Executive Director Appointment Southampton, UK – 30 September 2021: Synairgen plc (LSE: SNG), the drug discovery, development and commercialisation...
Interim results for the six months ended 30 June 2021
30. September 2021 02:01 ET
|
Synairgen plc
Synairgen plc(‘Synairgen’ or the ‘Company’) Interim results for the six months ended 30 June 2021 Scaling up and preparing for Phase III COVID-19 trial data read-out Webcast today at 13:00 BST ...
Preliminary results for the year ended 31 December 2020
12. Mai 2021 07:00 ET
|
Synairgen plc
Press release Synairgen plc(‘Synairgen’ or the ‘Company’) Preliminary results for the year ended 31 December 2020 Significant progress continues towards a treatment for COVID-19 ...
Preliminary results for the year ended 31 December 2020
12. Mai 2021 02:00 ET
|
Synairgen plc
Press release Synairgen plc(‘Synairgen’ or the ‘Company’) Preliminary results for the year ended 31 December 2020 Significant progress continues towards a treatment for COVID-19 Southampton, UK –...
Synairgen plc - Interim results for the six months ended 30 June 2020
29. September 2020 07:00 ET
|
Synairgen plc
Press release Synairgen plc(‘Synairgen’ or the ‘Company’) Interim results for the six months ended 30 June 2020 Southampton, UK – 29 September 2020: Synairgen plc (LSE: SNG), the respiratory drug...
Synairgen plc - Update on expanded SG016 trial for patients with COVID-19:Synairgen initiates dosing of SNG001 in home setting to treat patients earlier in the illness
26. Mai 2020 07:00 ET
|
Synairgen plc
Press release Synairgen plc(‘Synairgen’ or the ‘Company’) Update on expanded SG016 trial for patients with COVID-19:Synairgen initiates dosing of SNG001 in home setting to treat patients earlier in...
Synairgen plc: Preliminary results for the year ended 31 December 2019
26. Mai 2020 07:00 ET
|
Synairgen plc
Press release Synairgen plc(‘Synairgen’ or the ‘Company’) Preliminary results for the year ended 31 December 2019 Southampton, UK – 26 May 2020: Synairgen plc (LSE: SNG), the respiratory drug...